ACCPL2024-10-012025-03-31ACCPL2025-03-31ACCPL2024-03-31ACCPL2024-04-012025-03-31ACCPL2024-10-012025-03-31in-capmkt:OtherExpenses1MemberACCPL2024-04-012025-03-31in-capmkt:OtherExpenses1MemberACCPL2024-10-012025-03-31RelatedPartyTransactionDomain1ACCPL2024-09-30RelatedPartyTransactionDomain1ACCPL2025-03-31RelatedPartyTransactionDomain1ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain2ACCPL2024-09-30RelatedPartyTransactionDomain2ACCPL2025-03-31RelatedPartyTransactionDomain2ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain3ACCPL2024-09-30RelatedPartyTransactionDomain3ACCPL2025-03-31RelatedPartyTransactionDomain3ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain4ACCPL2024-09-30RelatedPartyTransactionDomain4ACCPL2025-03-31RelatedPartyTransactionDomain4ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain5ACCPL2024-09-30RelatedPartyTransactionDomain5ACCPL2025-03-31RelatedPartyTransactionDomain5ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain6ACCPL2024-09-30RelatedPartyTransactionDomain6ACCPL2025-03-31RelatedPartyTransactionDomain6ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain7ACCPL2024-09-30RelatedPartyTransactionDomain7ACCPL2025-03-31RelatedPartyTransactionDomain7ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain8ACCPL2024-09-30RelatedPartyTransactionDomain8ACCPL2025-03-31RelatedPartyTransactionDomain8ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain9ACCPL2024-09-30RelatedPartyTransactionDomain9ACCPL2025-03-31RelatedPartyTransactionDomain9ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain10ACCPL2024-09-30RelatedPartyTransactionDomain10ACCPL2025-03-31RelatedPartyTransactionDomain10ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain11ACCPL2024-09-30RelatedPartyTransactionDomain11ACCPL2025-03-31RelatedPartyTransactionDomain11ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain12ACCPL2024-09-30RelatedPartyTransactionDomain12ACCPL2025-03-31RelatedPartyTransactionDomain12ACCPL2024-10-012025-03-31RelatedPartyTransactionDomain13ACCPL2024-09-30RelatedPartyTransactionDomain13ACCPL2025-03-31RelatedPartyTransactionDomain13ACCPL2024-10-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares000000ACCPLNOTLISTEDINE0T8T01010ACCRETION PHARMACEUTICALS LIMITEDSMEEquity2024-04-012025-03-312025-06-102025-06-04INRLakhsHalf YearlyYearlySingle segmentPHARMACEUTICALS2025-06-1017:00:002025-06-1017:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruefalseNANAfalsetrue2024-07-25https://accretionpharma.com/falsefalseThere is no default in loan or debt securities payment.2024-10-012025-03-31AuditedStandalone3881200007910003889110002921910000-12906000213490007427000407500012072000324208000647030000647030000647030001948200019320002141400043289000000432890004328900081700000105.35.31. The above Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10/06/2025. <BR> 2. The previous periods figures have been regrouped whereever necessary. <BR> 3. The Statutory auditors of the company have carried out an Audit and issued "Independent Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. <BR> 4. The Company has been incorporated as on 29th November, 2023 by conversion of Partnership Firm. Hence, Previous year's Audited figures of the Company consist of period between 29/11/2023 to 31/03/2024. <BR> 5. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto and which is considered as only reportable primary business segment as per Accounting Standard "Segment Reporting" (AS - 17). As such, no separate disclosure for Segment Reporting is made. <BR> 6. The figures for the half year ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the first half year of the financial year. <BR> 7. The company had made an intial public offering (IPO) of 29,46,000 equity shares of face value of Rs. 10 each fully paid up for cash at a price of Rs. 101 per equity shares (including share premium of Rs. 91 per equity share) aggregating to Rs. 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21st May, 2025. <BR> 8. Earning per share is not retrospectively effected due to Fresh issue of equity as it is considered as Non-Adjusting event as per AS 4 'Contingencies and Events Occurring After the Balance Sheet Date'.2024-04-012025-03-31AuditedStandalone5737620009440005747060004371010000-38004000367490001436900077450001910800047706800097638000097638000097638000277710001932000297030006793500000067935000679350008170000010711650008.488.48Other Expenses12072000Other Expenses191080008170000071165000152865000011676000194500001362100012935800018390000574720007586200044800026590000232258000398744000609090000609090000760000160800063277000020609700011661100050800001103600012150003354670003987440001436900077450000000000022114000-61338000-58567000-143800010087000638340004501000-42921000-20807000768310000001857700005825400000582540000000000001610800000000000000-1610800000-1610800030000000000574310000143690000-754000-4255400000-42554000-4080000-408000916000508000ACCRETION PHARMACEUTICALS LIMITED******Mr. Harshad Nanubhai Rathod******KMPRemunerationApproved99800000ACCRETION PHARMACEUTICALS LIMITED******Mr. Mayur Popatlal Sojitra******KMPRemunerationApproved99800000ACCRETION PHARMACEUTICALS LIMITED******Mr. Vivek Ashok Kumar Patel******KMPRemunerationApproved99800000ACCRETION PHARMACEUTICALS LIMITED******Mr. Hardik Mukundbhai Prajapati******KMPRemunerationApproved89900000ACCRETION PHARMACEUTICALS LIMITED******Mrs. Rathod Pooja Harshad******Relative of KMPAny other transactionSalary ExpensesApproved55000000ACCRETION PHARMACEUTICALS LIMITED******Mrs. Shweta Sojitra******Relative of KMPAny other transactionSalary ExpensesApproved55000000ACCRETION PHARMACEUTICALS LIMITED******Mrs. Ankita Vivek Patel******Relative of KMPAny other transactionSalary ExpensesApproved50000000ACCRETION PHARMACEUTICALS LIMITED******Mrs. Vaishaki Hardik Prajapati******Relative of KMPAny other transactionSalary ExpensesApproved55000000ACCRETION PHARMACEUTICALS LIMITED******Accretion Nutraveda Private Limited******Relative of KMPPurchase of goods or servicesApproved5300000ACCRETION PHARMACEUTICALS LIMITED******Accretion Nutraveda Private Limited******Relative of KMPSale of goods or servicesApproved373000000ACCRETION PHARMACEUTICALS LIMITED******Accretion INC******Relative of KMPSale of goods or servicesApproved124200000ACCRETION PHARMACEUTICALS LIMITED******Accretion INC******Relative of KMPPurchase of goods or servicesApproved106400000ACCRETION PHARMACEUTICALS LIMITED******Accretion Lifecare Pvt ltd******Relative of KMPSale of goods or servicesApproved143530000844800026485000AuditedtrueV S S B & Associatestrue2026-10-31